Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 27/100

Termination Rate

0.0%

0 terminated out of 34 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

18%

6 trials in Phase 3/4

Results Transparency

47%

8 of 17 completed with results

Key Signals

8 with results100% success

Data Visualizations

Phase Distribution

15Total
P 1 (2)
P 2 (7)
P 3 (3)
P 4 (3)

Trial Status

Completed17
Recruiting6
Unknown4
Active Not Recruiting4
Withdrawn3

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 17 completed trials

Clinical Trials (34)

Showing 20 of 20 trials
NCT05596539RecruitingPrimary

Prospective, Longitudinal, Observational Registry of Adult Patients With Hypophosphatasia (REG-HYPO)

NCT07390240RecruitingPrimary

The Effect of Monoallelic Variants in the ALPL Gene on the Natural Course of Hypophosphatasia in Russia

NCT03655223Active Not Recruiting

Early Check: Expanded Screening in Newborns

NCT06079281Phase 3Active Not RecruitingPrimary

Phase 3 Study of ALXN1850 Versus Placebo in Adolescent and Adult Participants With HPP Who Have Not Previously Been Treated With Asfotase Alfa

NCT06079359Phase 3Active Not RecruitingPrimary

Phase 3 Study of ALXN1850 in Treatment-Naïve Pediatric Participants With HPP

NCT05062629CompletedPrimary

United States Hypophosphatasia Molecular Research Center

NCT06079372Phase 3Active Not RecruitingPrimary

Phase 3 Study of ALXN1850 in Pediatric Participants With HPP Previously Treated With Asfotase Alfa

NCT02237625RecruitingPrimary

Natural History Study of Patients With Hypophosphatasia (HPP)

NCT05234567RecruitingPrimary

A Prospective Sub-Study of the Global Hypophosphatasia Registry

NCT06015750Phase 4WithdrawnPrimary

Mitigate Immune-Mediated Loss of Therapeutic Response to Asfotase Alfa (STRENSIQ®) for Hypophosphatasia

NCT01793168Recruiting

Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford

NCT05890794Phase 1CompletedPrimary

Pilot Trial of Single Dose Ilofotase Alfa in Hypophosphatasia

NCT06574282RecruitingPrimary

Characteristics of Hypophosphatasia in Adult Patients in Rheumatology and Their Value in Developing an Algorithm to HPP-diagnosis - the COHIR Multi-center Study

NCT04980248Phase 1CompletedPrimary

Study of ALXN1850 in Participants With Hypophosphatasia (HPP)

NCT04195763CompletedPrimary

Patient Reported Outcomes in Adults With Pediatric-onset Hypophosphatasia Treated With Strensiq® (Asfotase Alfa)

NCT06161142UnknownPrimary

Characteristics of Hypophosphatasia in Adult Patients in Rheumatology

NCT02796885CompletedPrimary

Characterisation of Adult-Onset Hypophosphatasia

NCT00894075Phase 2WithdrawnPrimary

Safety and Efficacy Study of ENB-0040 in Juvenile Patients With Hypophosphatasia (HPP)

NCT04018287UnknownPrimary

Circulating miRNAs and Bone Microstructure in Adults With Hypophosphatasia

NCT04222452UnknownPrimary

The PORTRAIT Study

Scroll to load more

Research Network

Activity Timeline